SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Josh C. Pleasure, M.D. who wrote (87)11/2/1996 10:05:00 AM
From: Sean Janzen   of 1501
 
Josh,

As stated in the First Honolulu Securities article "Inflazyme's TB diagnostic test, with conservative projected revenues to Inflazyme of $25-30 million by the year 2000, could by itself, substantiate a market capitalization of $60-75 million." I see this as the glue that supports the share price while Apanol undergoes Human Clinical Testing.

IZP's arsenal contains 50 compounds with the potential to produce 500 different drugs. Would poor human clinical trials in one drug spell the death of IZP? I hope not.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News